Best-practice indicators in Psoriatic disease care

Best-practice indicators in Psoriatic disease care

<br><strong>Objective: </strong>In 2016, members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), in collaboration with KPMG LLP (UK), conducted a study to measure care in psoriatic arthritis (PsA). A key finding was that centers do not usuall...

Full description

Bibliographic Details
Main Authors:	Helliwell, P, Favier, G, Gladman, D, Soriano, E, Kirkham, B, Coates, L, Puig, L, Boehncke, W, Thaçi, D
Format:	Journal article
Language:	English
Published:	Journal of Rheumatology 2019

Similar Items

Assessing disease activity in psoriatic arthritis: a literature review
by: Tucker, L, et al.
Published: (2018)

More than skin-deep: the many dimensions of the psoriatic disease
by: Wolf-Henning Boehncke, et al.
Published: (2014-04-01)

Current concepts and unmet needs in psoriatic arthritis
by: Mahmood, F, et al.
Published: (2017)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
by: Coates, L, et al.
Published: (2021)

Sustained very low disease activity and remission in psoriatic arthritis patients
by: Lubrano, E, et al.
Published: (2019)

Assessing Disease Activity in Psoriatic Arthritis: A Literature Review
by: Laura J. Tucker, et al.
Published: (2018-11-01)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
by: Coates, L, et al.
Published: (2016)

Classification and outcome measures for psoriatic arthritis
by: Leung, Y, et al.
Published: (2018)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
by: Coates, L, et al.
Published: (2019)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Gladman, DD, et al.
Published: (2022)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
by: Coates, L, et al.
Published: (2016)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
by: Helliwell, P, et al.
Published: (2018)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
by: D.D. Gladman
Published: (2011-09-01)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
by: Tillett, W, et al.
Published: (2020)

Non tropical pharmacological treatment of early, untreated (Dmard-Naïve) psoriatic disease: A systematic review
by: De Marco, G, et al.
Published: (2019)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus‐based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis
by: Coates, L, et al.
Published: (2017)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
by: Coates, L, et al.
Published: (2022)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
by: Ennio Lubrano, et al.
Published: (2019-08-01)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
by: Mease, PJ, et al.
Published: (2019)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
by: P.S. Helliwell
Published: (2011-09-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Dafna D. Gladman, et al.
Published: (2022-02-01)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
by: Mease, P, et al.
Published: (2017)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
by: Helliwell, P, et al.
Published: (2018)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
by: Soriano, ER, et al.
Published: (2023)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
by: Alexis Ogdie, et al.
Published: (2023-05-01)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
by: Gladman, DD, et al.
Published: (2018)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
by: Helliwell, PS, et al.
Published: (2022)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
by: Ogdie, A, et al.
Published: (2023)

The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study
by: Helliwell, PS, et al.
Published: (2023)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
by: Ye, W, et al.
Published: (2018)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
by: Tillett, W, et al.
Published: (2017)

Classification and Outcome Measures for Psoriatic Arthritis
by: Ying Ying Leung, et al.
Published: (2018-09-01)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
by: Coates, L, et al.
Published: (2018)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
by: Ye, W, et al.
Published: (2021)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
by: Mease, P, et al.
Published: (2018)

A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: a call to action
by: Gratacós, J, et al.
Published: (2021)

Psoriatic Arthritis: A Review
by: Farrouq Mahmood, et al.
Published: (2016-07-01)

What should be the primary target of "treat to target" in psoriatic arthritis?
by: Coates, LC, et al.
Published: (2018)

Enhanced surveillance for the detection of psoriatic arthritis in a UK primary care psoriasis population: results from the TUDOR trial
by: McHugh, N, et al.
Published: (2024)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
by: Coates, L, et al.
Published: (2020)